Overview
- A phase 1 trial in 143 healthy adults found intranasal CR9114 safe and well tolerated, with nasal samples neutralizing multiple influenza A and B strains, including a bird flu strain detected in China in 2013.
- Pharmacokinetic data showed an approximately three-hour half-life in the nose, indicating that twice-daily administration maintains protective levels.
- Direct nasal delivery produced up to 4,600-fold higher antibody concentrations on the nasal lining than intravenous administration while using smaller doses.
- Preclinical challenge studies demonstrated protection in mice and macaques against diverse influenza A and B viruses.
- Researchers plan human efficacy studies to verify infection prevention in people, and outside experts describe the spray as a short-term tool for high-risk situations rather than a replacement for vaccination.